Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
SymbolNASDAQ:CRON
CUSIPN/A
Phone212-590-9070
Debt
Debt-to-Equity Ratio0.02
Current Ratio52.98
Quick Ratio44.71
Price-To-Earnings
Trailing P/E Ratio1,384.00
Forward P/E Ratio-1,354.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.15 million
Price / Sales760.43
Cash Flow$0.0220 per share
Price / Cash615.09
Book Value$0.47 per share
Price / Book28.81
Profitability
EPS (Most Recent Fiscal Year)$0.01
Net Income$1.92 million
Net Margins30.64%
Return on Equity2.23%
Return on Assets2.05%
Miscellaneous
Employees148
Outstanding Shares176,910,000
Market Cap$2.05 billion
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
When is Cronos Group's next earnings date?
What is the consensus analysts' recommendation for Cronos Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Are investors shorting Cronos Group?
Cronos Group saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 20,590,632 shares, an increase of 21.5% from the August 15th total of 16,945,292 shares. Based on an average daily trading volume, of 32,786,347 shares, the short-interest ratio is currently 0.6 days. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), Conversion Labs (CVLB), ImmuDyne (IMMD), FitLife Brands (FTLF) and True Drinks (TRUU).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Has Cronos Group been receiving favorable news coverage?
Media coverage about CRON stock has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cronos Group earned a daily sentiment score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Cronos Group.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Commonwealth Equity Services LLC (0.04%), Lourd Capital LLC (0.03%), Bank of Montreal Can (0.03%), Jane Street Group LLC (0.03%), PEAK6 Investments L.P. (0.02%) and Farmers Trust Co. (0.02%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can.
Which institutional investors are buying Cronos Group stock?
CRON stock was acquired by a variety of institutional investors in the last quarter, including Lourd Capital LLC, PEAK6 Investments L.P., Commonwealth Equity Services LLC, Jane Street Group LLC, Sigma Planning Corp, Gerber Kawasaki Wealth & Investment Management, Tower Research Capital LLC TRC and Farmers Trust Co..
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $13.21.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.05 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
